Alnylam Posts 3Q EPS of $15.72
ALNY sits 19% above its 52-week low of $197.81.
Summary
Alnylam reported third-quarter EPS of $15.72, a striking figure against a $31B market cap and a stock at $235.02, with adjusted EPS of USD 16.26 versus an IBES estimate of USD 1.62. The quarter brought net income of $2.17B and revenue of $1.46B, up 17%, and the company booked a $1.9B benefit from income taxes. Total TTR net product revenues were $1.15B, up 59%, and total net product revenues were $1.29B, up 52%. That follows a Q2 in which revenue jumped 67% to $1.29B and the company swung to $164.5M of net income on the AMVUTTRA ATTR-CM launch, so the print extends an already steep growth run. Alnylam said it is on track to achieve its 2026 financial guidance.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Alnylam's Q3 total revenues rose 17% to $1.46B, with total TTR net product revenues of $1.15B (59% growth) and total net product revenues of $1.29B (52% growth).
At the time of this announcement, ALNY was trading at $235.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.1B. The 52-week trading range was $197.81 to $484.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.